The effects of route of exposure, time of exposure and metabolism of 2-butoxyethanol (BE) on the contact hypersensitivity response (CHR) were evaluated in female BALB/c mice. Mice were either orally exposed to 50, 150 or 400 mg BE/kg or topically exposed to 0.25, 1.0, 4.0 or 16.0 mg BE on the ear and the oxazolone (OXA)-induced CHR evaluated by measuring ear thickness before and after OXA challenge. While no modulation was observed following oral exposure to BE, topical exposure resulted in a signi cant decrease in the CHR. Application of 4.0 mg BE in 4:1 acetone and olive oil (AOO) vehicle at the time of sensitization, challenge or both, decreased the CHR by 18%, 18% and 22%, respectively. A time course study of the effects of topical exposure to 4.0 mg BE/ear during the challenge phase of the CHR revealed that BE must be applied at the time of OXA challenge to signicantly reduce the ear swelling response. In order to determine if metabolism of topically applied BE was required for suppression of the CHR, butoxyacetic acid (BAA), the primary metabolite of BE, was applied to the ear immediately following OXA challenge. No topical dose of BAA (2.0, 4.0 and 8.0 mg BAA/ear) administered in this study altered the CHR. Blocking the metabolism of BE by oral administration of 4-methylpyrazole (MP), further reduced OXAinduced ear swelling when compared to mice exposed to BE without MP treatment. Taken together, these studies indicated that suppression of the CHR in mice following topical exposure to this glycol ether was due to the activity of BE itself and was not dependent on metabolic activation of the compound. Further studies were undertaken to identify a potential mechanism of BE-induced reduction of the CHR. Epidermal cells from untreated BALB/c mice were isolated and exposed to BE in vitro (10 ¡ 12 , 10 ¡ 10 , 10 ¡ 8 , 10 ¡ 6 and 10 ¡ 4 M BE). In vitro exposure to BE at these concentrations did not signi cantly affect expression of MHC class II surface protein or protein synthesis in epidermal Langerhans cells, failing to provide in vitro evidence that BE-associated suppression of the CHR is associated with a reduction in MHC class II expression.
2-Butoxyethanol (BE), also known as ethylene glycol monon-butyl ether, is the most widely produced glycol ether of the ethylene glycol series (Greenspan et al. 1995) and is used in both industrial and consumer products as an organic solvent and emulsifying agent. The high potential for occupational and public exposures to BE has been recognized by both United States and international chemical safety and regulatory bodies (National Industrial Chemicals Noti cation and Assessment Scheme [NICNAS] 1996; National Institute for Occupational Safety and Health, National Occupational Exposure Survey [NIOSH, NOES] 1981 -1983 and has led to the publication of a comprehensive evaluation of BE in cleaning products by the Australian government (NICNAS 1996) . Toxicological studies have indicated that several members of the glycol ether family can alter immune function and integrity of immune organs in rodent models, varying in degree with dose, route of exposure, species or strain, sex, and age (Exon et al. 1991; Krasavage 1986; NIOSH 1990; Smialowicz et al. 1992; Williams et al. 1995) .
Immune effects of glycol ethers have been most thoroughly studied in 2-methoxyethanol (ME), differing in structure from BE by two aliphatic carbons, and little is known about the immunomodulatory potential of any other glycol ether. Oral exposure to ME has been shown to cause suppression of humoral immunity as well as decreased thymus weight in F344 rats (Smialowicz et al. 1991a) . Topical exposure to ME has also been shown to suppress humoral immunity and decrease both spleen and thymus weight in F344 rats (Williams et al. 1995) .
This immunosuppression associated with ME exposure has a demonstrated dependence on metabolism of ME to methoxyacetic acid (MAA), initiated by alcohol dehydrogenas e (Smialowicz et al. 1991b) .
BE has tested positive as a topical irritant in rabbits by both European Economic Community (EEC) and Draize methods (Zissu 1995) . Out of nine glycol ethers evaluated, only BE and isopropoxyethanol caused irritation on contact with the skin (Zissu 1995) . BE is not a contact sensitizer in humans (Greenspan et al. 1995) or guinea pigs (Zissu 1995) . Glycol ethers readily penetrate the skin (Johanson and Fernstrom 1986; Kezic et al. 1997; Tyler 1984) , and absorption of BE has been demonstrated following topical exposures in humans (Johanson, Boman, and Dynesius 1988) , guinea pigs (Johanson and Fernstrom 1986) , and rats (Sabourin et al. 1992) . Topical application of xenobiotic agents such as pentamidine isethionate (Blaylock et al. 1991) and T-2 toxin (Blaylock et al. 1993 ) has been shown to suppress the contact hypersensitivity response (CHR) in BALB/c mice, associated with a reduction in major histocompatability complex (MHC) class II expression. Suppression of the CHR by ultraviolet B (UVB) radiation may be mediated by a loss of the ability of epidermal Langerhans cells (LC) to stimulate Th1 cells (Simon et al. 1990) . In this study, we report data from female BALB/c mice indicating that topical but not oral exposure to BE suppresses the oxazalone (OXA)induced CHR without causing topical irritation. We demonstrate the immunomodulatory activity of topically applied BE in the CHR and investigate whether alteration of MHC class II expression in LC could be a mechanism of suppression of the CHR following topical exposure to BE.
MATERIALS AND METHODS

Animals
Female BALB/c mice were purchased from Charles River Laboratories (Frederick, Maryland) at 5 weeks of age. Animals were allowed a minimum 1-week acclimation period and used for experiments at ages 6 to 10 weeks old. Animals were housed under controlled temperature (22 ± C § 2 ± C), humidity (40-60%), and photoperiod (12/12-hour light/dark cycle). All animals were maintained on Teklad Mouse/Rat Diet (Harlan Teklad, Madison, Wisconsin) and tap water ad libitum.
Contact Hypersensitivity Response
The CHR was measured using the method of Asherson and Ptak (1968) , with some modi cation, to evaluate the mouse ear swelling response to a contact allergen. Brie y, mice were separated into ve per treatment group, anaesthetized with ether, and shaved on the back from the top of the shoulder to the mid-dorsal region. Mice were sensitized topically by application of 25 ¹l of 2% (w/v) 4-ethoxymethylene-2-pheny l OXA (Sigma, St Louis, Missouri) dissolved in 4:1 reagent-grade acetone:olive oil (AOO) vehicle. Five days after sensitization, mice were challenged with 20 ¹l of 0.5% (w/v) OXA in AOO (a nonirritating dose), 10 ¹l on both the dorsal and ventral sides of the right ear. The same quantity of vehicle was placed on the left ear to control for any vehicle-related effects. Ear thickness was measured, using a spring-loaded Oditest D 1000 micrometer (Dryer, Lancaster, Pennsylvania), prior to challenge as well as 24 and 48 hours post challenge. Change in ear thickness at 24 hours post challenge (the time of maximum observed ear swelling) was compared in treated and control animals.
Oral or Topical Exposure to BE and the CHR BE was obtained from Sigma (St. Louis, Missouri). BE was diluted in deionized (DI) water to produce various concentrations. Mice were dosed with 50, 150, or 400 mg BE/kg/day in 0.1 to 0.15 ml for 10 consecutive days by oral gavage and OXA-sensitized on the 5th or the 10th day of BE treatment. Other groups of mice were topically exposed to 0.25, 1.0, 4.0, or 16.0 mg BE in AOO vehicle/ear in a total volume of 20 ¹l (10 ¹l onto both dorsal and ventral sides of the right ear) immediately after challenge with OXA. A preliminary irritancy study revealed that these doses of BE did not cause topical irritation (data not shown). The time-dependent effects of topical BE exposure on the CHR were evaluated by applying 4.0 mg BE in AOO on the skin at sensitization (25 ¹l on the back), at challenge (20 ¹l on the ear), or at both sensitization and challenge in separate groups of mice. In addition, the effects of timing of topical BE exposure relative to OXA challenge were investigated by applying 4.0 mg BE on the ear at 10, 6, 3, or 1 hour before or after antigen challenge or immediately after challenge.
Topical Exposure to BE and MP Treatment and the CHR
The alcohol dehydrogenase inhibitor, 4-methylpyrazole hydrochloride (MP), was obtained in crystal form (99% purity) from Aldrich (Milwaukee, Wisconsin). Mice were administered either 100 mg MP/kg body weight dissolved in DI water (see Smialowicz et al. 1991b) or DI water only in 0.15 to 0.22 ml daily, from the day of OXA sensitization to the day of OXA challenge. Both MP-and DI water-pretreated mice were topically exposed to either 4.0 mg BE in AOO vehicle or AOO vehicle alone (control) on the ear immediately following topical OXA challenge at the same site. All doses of MP and DI water were administered by oral gavage.
Topical Exposure to BAA and the CHR
Butoxyacetic acid (BAA) was synthesized and generously supplied by Dr. Ron Hill, Associate Professor of Medicinal Chemistry at The University of Louisiana at Monroe. Purity of BAA was assessed by high performance liquid chromatography (HPLC) and determined to be not less than 98%. BAA was diluted in AOO vehicle and administered topically at doses of 2.0, 4.0, and 8.0 mg BAA/ear in a total volume of 20 ¹l (10 ¹l onto both dorsal and ventral sides of the right ear) immediately following challenge with OXA. A preliminary irritancy study revealed that these doses of BAA and up to 12.0 mg BAA did not cause topical irritation (data not shown). Mice in the control group received 20 ¹l AOO (10 ¹l onto both dorsal and ventral sides of the right ear) following challenge with OXA.
In Vitro Exposure to BE
Freshly isolated epidermal cells (EC) were exposed in vitro to 10 ¡10 , 10 ¡8 , and 10 ¡6 M BE in culture media for 48 hours at 37 ± C, 5% CO 2 , and 60% humidity followed by isolation of LC for ow cytometric analysis of MHC class II surface protein expression and LC viability. In a separate experiment, freshly isolated EC were exposed in vitro to 10 ¡12 , 10 ¡10 , 10 ¡8 , 10 ¡6 , and 10 ¡4 M BE in culture media for 48 hours as described above to investigate the effect of BE on protein synthesis in these cells.
Epidermal Cell Preparation and Langerhans Cell Enrichment
Primary cell cultures were maintained in RPMI 1640 supplemented with 10% heat-inactivated, de ned fetal bovine serum (FBS) (Hyclone Laboratories, Logan, Utah), 2 mM L-glutamine (Mediatech, Washington, DC), 1% nonessential amino acids (Mediatech), 1 mM sodium pyruvate (Sigma), 50 ¹g/ml gentamicin sulfate (Sigma), and 5 £ 10 ¡5 M 2-mercaptoethanol (Sigma). The supplemented medium was sterilized by ltration, using a 500-ml Nalgene lter apparatus containing a 0.22-micron lter (Nalgene, Rochester, NY). Preparations of freshly isolated EC were obtained by a method previously described by Tamaki et al. (1979) . Brie y, epidermal sheets derived from trypsinized mouse ear and trunk skin were thoroughly minced and disaggregated to form a single cell suspension of EC. EC were then washed in supplemented RPMI culture media and adjusted to appropriate concentrations for (a) ow cytometric analysis or (b) evaluation of protein synthesis. For ow cytometric analysis, further isolation of LC was achieved by a method described by Blaylock et al. (1991) following 48 hours in vitro exposure to BE. Brie y, cells were pooled, by treatment group, from culture asks and washed in phosphate-buffere d saline (PBS). EC were then adjusted to 1-1.5 £ 10 7 cells in 5 ml PBS and pipetted onto 3 ml lympholyte M (Accurate Chemicals, San Diego, California) for density gradient separation of LC. After centrifugation (300 £ g for 10 minutes at 22 ± C), LC present at the interface of the two density gradients were carefully aspirated using a Pasteur pipet. LC were then washed and adjusted to a concentration of 0.5-1 £ 10 6 cells/ml for staining. Viability of LC was determined by trypan blue exclusion observed under an inverted microscope using a hemacytometer to count cells. LC with 86% or greater viability were stained for ow cytometry.
Flow Cytometric Analysis
Freshly isolated LC were adjusted to 0.5-1 £ 10 6 total cells, washed in PBS, and resuspended in 100 ¹l of a 1:50 dilution of Fc Block (Pharmingen, San Diego, California) to inhibit nonspeci c binding of the uoroscein isothiocyanate (FITC)labeled antibody. Following a 5-minute incubation on ice and in the dark with Fc block, LC were stained with 100 ¹l of a 1:50 dilution of FITC-conjugated goat anti-mouse Ia d monoclonal antibody (Pharmingen) in PBS for 20 minutes on ice and in the dark. LC were then washed three times and resuspended in 1 ml of ow cytometer sheath uid (Becton Dickinson, San Jose, CA) and propidium iodide (PI) (Sigma) (0.5 ¹g/ml). LC were allowed to stain with PI for 5 minutes in the dark and then evaluated by ow cytometry using a FACSCalibur Model ow cytometer (Becton Dickinson). Instrument settings were optimized using (1) unstained cells, (2) cells stained with an antibody isotype control (FITC-conjugated goat anti-mouse IgG3) (Pharmingen), (3) cells stained with either PI or goat anti-mouse Ia d monoclonal antibody, and (4) cells stained with both PI and goat anti-mouse Ia d monoclonal antibody.
In Vitro Protein Synthesis in BE-Exposed EC
Protein synthesis was evaluated in vitro in BE-treated EC using a method previously described by Blaylock et al. (1993) . Freshly isolated EC were added to individual wells of a atbottom, 96-well microtiter plate for a total of 1 £ 10 6 cells/well in 200 ¹l RPMI. BE was added to triplicate wells for nal concentrations of 10 ¡12 , 10 ¡10 , 10 ¡8 , 10 ¡6 , and 10 ¡4 M BE/well. Each well was pulsed with 1 ¹Ci 3 H-Leu (NEN Life Science Products, Boston, Massachusetts) in 10 ¹l RPMI, and microtiter plates were placed in a 37 ± C incubator for 48 hours at 5% CO 2 and 60% humidity. Cells were harvested on 12-well cell harvester lter mats with DI water using a Skatron Classic Cell Harvester. Filter mat disks were placed in 7 ml scintillation vials containing 4 ml ScintiSafe scintillation uid. Uptake of 3 H-Leu by intact cells, indicating de novo protein synthesis, was determined in a Beckman liquid scintillation counter and is reported as cpm (counts per minute). Stimulated protein synthesis was evaluated by adding 1 ng of phorbol 12-myristate-acetate (PMA) (Sigma) to each well prior to incubation with 3 H-Leu.
Statistical Analysis
All data are representative of replicate studies (repeated at least three times) and values are presented as mean § SEM. Each treatment group consisted of at least ve animals per group (N D 5). All data were analyzed by one-way analysis of variance (ANOVA), followed by Scheffe's post hoc test to establish signi cant differences between group means. Statistical significance was determined at p < :05.
RESULTS
Mice that received doses of 50, 150, or 400 mg BE/kg/day for 10 consecutive days by oral gavage did not exhibit a signi cantly altered OXA-induced CHR as measured by ear swelling 24 hours post challenge (Figure 1 ). This was true for mice sensitized on the last day of BE exposure and challenged 5 days later (Figure 1 ) and for mice sensitized on the 5th days of BE exposure and
FIGURE 1
Contact hypersensitivity response to OXA in mice exposed to 50, 150, or 400 mg BE in DI water or DI water only (Veh Control) daily by oral gavage for 10 consecutive days. Mice were sensitized with OXA on the last day of BE treatment. Results represent change in ear thickness 24 hours after OXA challenge. A separate group of mice that were not exposed to BE nor to OXA was included as a negative control (No OXA). Each bar value shows the group mean § SEM (N D 5) from a representative experiment. There were no signi cant differences among the treatment groups.
FIGURE 2
Contact hypersensitivity response to OXA in mice topically exposed to 0.25, 1.0, 4.0, or 16.0 mg BE in AOO vehicle or AOO vehicle only (Veh Control) on the ear immediately after OXA challenge. Results represent change in ear thickness 24 hours after OXA challenge. A separate group of mice that were not exposed to BE nor to OXA was included as a negative control (No OXA). Each bar value shows the group mean § SEM (N D 5) from a representative experiment. ¤ Signi cant difference from Veh Control at p < :05.
FIGURE 3
Contact hypersensitivity response to OXA in mice topically exposed to 4.0 mg BE in AOO vehicle at sensitization, at challenge, or both at sensitization and at challenge. (A) BE treatment on the shaved back immediately after sensitization;
(B) BE treatment on the ear immediately after challenge; (C) BE treatment immediately after both sensitization and challenge. Mice in Veh Control group received AOO vehicle only on the ear immediately after OXA challenge and no BE. Results represent change in ear thickness 24 hours after OXA challenge. A separate group of mice that were not exposed to BE nor to OXA was included as a negative control (No OXA). Each bar value shows the group mean § SEM (N D 5) from a representative experiment. ¤ Signi cant difference from Veh Control at p < :05.
challenged 5 days later (data not shown). By contrast, topical exposure to BE signi cantly suppressed the OXA-induced CHR at a dose of 4.0 mg BE/ear ( Figure 2 ) but not at any other dose administered (0.25, 1.0, 2.0, 6.0, 8.0, 12.0, and 16.0 mg BE/ear) (data from doses of 6.0, 8.0, and 12.0 mg BE/ear not shown). Potential differences associated with topical application of BE during the sensitization and challenge phases of the CHR were investigated to determine the period of susceptibility to BE's suppressive effects on the CHR. When 4.0 mg BE was applied on the skin at the site of OXA exposure either at the time of sensitization or the time of challenge, the ear swelling response was decreased by 18%. When the same dose of BE was applied to the site of OXA exposure at both sensitization and challenge, ear swelling was reduced by 22% ( Figure 3) . In order to determine whether timing of topical exposure to BE on the ear during OXA challenge would signi cantly alter the potential of BE to suppress the CHR, 4.0 mg BE was applied to the ears of mice 10, 6, 3, or 1 hour before or after OXA challenge or immediately following OXA challenge. Results indicated that the ability of BE to reduce ear swelling depended entirely on the time of BE application, such that only when BE was administered immediately following antigen challenge did it signi cantly reduce OXA-induced ear swelling (Figure 4 ). Our investigations of the
FIGURE 4
Contact hypersensitivity response to OXA in mice topically exposed to 4.0 mg BE in AOO vehicle. BE was applied at the challenge site (on the ear) at 10, 6, 3, or 1 hour(s) before or after OXA challenge or immediately after OXA challenge. Mice in Veh Control group received AOO vehicle only on the ear immediately after OXA challenge and no BE. Results represent change in ear thickness 24 hours after OXA challenge. A separate group of mice that were not exposed to BE nor to OXA was included as a negative control (No OXA). Each bar value shows the group mean § SEM (N D 5) from a representative experiment. ¤ Signi cant difference from Veh Control at p < :05.
role of timing of topical BE exposure relative to the CHR suggest that the toxicokinetics of BE are critically important determinants of its immunomodulatory potential. In order to investigate whether BE-induced reduction of the CHR was dependent on metabolism of BE to BAA, mice were topically exposed to 2.0, 4.0, and 8.0 mg BAA on the ear immediately following OXA challenge to determine whether BAA would have a suppressive effect on ear swelling. No signi cant differences were observed between any BAA-exposed group and the vehicle control group, following OXA challenge ( Figure 5 ). Although these results indicated that BAA was not the active compound leading to suppression of the CHR, more evidence was needed to support the notion that BE was indeed the agent that inhibited normal elicitation of type IV hypersensitivity in these mice. To further examine the role of metabolism, the CHR was performed in mice pretreated with MP, an alcohol dehydrogenase inhibitor that blocks metabolism of BE. Mice, both with and without MP pretreatment, received a topical dose of 4.0 mg BE on the ear immediately following OXA challenge. This experiment demonstrated that inhibition of metabolism further enhanced the observed suppression of the CHR by BE ( Figure 6) .
MHC class II expression in epidermal LC isolated from pooled, primary culture epidermal cells exposed in vitro to 10 ¡10 , 10 ¡8 , or 10 ¡6 M BE was evaluated as a potential mechanism of
FIGURE 5
Contact hypersensitivity response to OXA in mice topically exposed to 2.0, 4.0, or 8.0 mg BAA in AOO vehicle or AOO vehicle only (OXA Control) on the ear immediately after OXA challenge. Results represent change in ear thickness 24 hours after OXA challenge. Each bar value shows the group mean § SEM (N D 5) from a representative experiment. There were no signi cant differences among the treatment groups.
FIGURE 6
Contact hypersensitivity response to OXA in mice topically exposed to 4.0 mg BE in AOO vehicle or AOO vehicle only (OXA Control) on the ear immediately after OXA challenge. MP, the alcohol dehydrogenase inhibitor, was given by oral gavage from the day of sensitization to the day of challenge in one group of BE-exposed mice and in one group that did not receive BE. Results represent change in ear thickness 24 hours after OXA challenge. Each bar value shows the group mean § SEM (N D 5) Note: Epidermal cells were exposed in vitro to 10 ¡10 , 10 ¡8 , and 10 ¡6 M BE for 48 hours, and LC were further isolated by density gradient separation. LC were double stained with FITC-conjugated mAb speci c for MHC Class II (Ia) antigen and propidium iodide (PI), which is nonselectively taken up by dead cells. FITC-conjugated mAb speci c for MHC class II positive and PI negative LC are represented by % of total LC. Viability of LC was determined after in vitro BE treatment both by PI staining and prior to ow cytometry by trypan blue (TB) exclusion. There were no signi cant differences in MHC class II expression or viability among BE-treated and nontreated LC following 48 hours' in vitro exposure. a % Live MHC class II positive Langerhans cells out of total sample. b Viability as determined by trypan blue (TB) exclusion in unstained samples.
c Viability as determined by propidium iodide (PI) uptake in PI-and FITC-stained samples.
BE-induced suppression of the CHR. Other studies have shown that one way in which xenobiotic exposure can suppress the CHR is by decreasing MHC class II expression and/or protein synthesis in LC, the primary antigen-presenting cells residing in the skin. In the present study, BE did not signi cantly alter viability or MHC class II expression in epidermal LC isolated from female BALB/c mice (Table 1 ). We also found that in vitro exposure of freshly isolated mouse epidermal cells to 10 ¡12 , 10 ¡10 , 10 ¡8 , 10 ¡6 , or 10 ¡4 M BE had no effect on either unstimulated or PMA-stimulated protein synthesis in these cells (Figure 7) .
DISCUSSION
The Occupational Safety and Health Guideline for BE prepared by the U.S. Department of Labor (NIOSH 1992) reported that acute exposures to BE can cause skin irritation and that chronic exposure to BE may result in dermatitis and hematuria. The main toxic effect of BE in rodents is hemolytic anemia; however, humans and certain mammals have reduced susceptibility to this effect (Ghanayem and Sullivan 1993) . Ghanayem, Burka, and Matthews (1987) showed that BE-induced hemolysis in rats is dependent on the metabolic conversion of BE by alcohol and aldehyde dehydrogenase s to BAA, which is the active hemolytic compound. Ghanayem (1989) suggested that the red blood cell (RBC) membrane may be the target of BE-associated hematotoxicity based on the observation that hemolysis of RBCs exposed in vitro to BAA is preceded by swelling of the cell and osmotic fragility.
FIGURE 7
Protein synthesis was measured in both stimulated (dark gray bars) and unstimulated (light gray bars) epidermal cells (EC) exposed in vitro to 10 ¡12 , 10 ¡10 , 10 ¡8 , 10 ¡6 , and 10 ¡4 M BE for 48 hours at 37 ± C and 5% CO 2 . EC were plated at 1 £ 10 6 cells/well and pulsed with 1 ¹Ci [ 3 H]leucine ( 3 H-Leu) over the culture period. 3 H-Leu uptake was determined in triplicate samples using a Beckman liquid scintillation counter and is reported as mean § SEM (N D 3) in cpm (counts per minute). Stimulated protein synthesis was evaluated by adding 1 ng of phorbol 12-myristate-acetate (PMA) (Sigma) to each well prior to incubation with 3 H-Leu. There were no signi cant differences among the treatment groups in both stimulated and unstimulated EC when compared to EC that were not exposed to BE (Control).
There is a paucity of information concerning the immunomodulatory potential of BE, although acute exposure studies in laboratory animals have indicated negative effects on the spleen and white blood cells (Krasavage 1986; NIOSH 1990) . Few studies are available in which glycol ethers other than ME have been assessed for immunological effects in laboratory animals. In one study, an increase in natural killer (NK) cell activity was demonstrated in Sprague-Dawley rats exposed to BE in their drinking water (Exon et al. 1991) . The same study reported that ME increased NK cell activity in these rats, but unlike BE, ME also caused thymic atrophy and immunosuppression. In a different study, BE and ME were among several glycol ethers tested for their ability to suppress the plaqueforming cell (PFC) response to T cell-independent antigen in Fischer 344 rats (Smialowicz et al. 1992) . In that study, ME, MAA, and methoxyethyl acetate (MEA) suppressed the PFC response, whereas BE, ethoxyethanol (EE), ethoxyacetic acid (EAA), and ethoxyethyl acetate did not suppress this humoral immune response. Glycol ethers have been shown to exhibit differential effects depending on the length of their alkyl chain. Chiewchanwit and Au (1995) found that BE was signi cantly cytotoxic to Chinese hamster ovary (CHO) cells in vitro and that cytotoxicity increased with alkyl chain length in the ethylene glycol monoalkyl ether series. These investigators also reported that the mutagenicity of the same glycol ethers decreased with increasing length of the alkyl chain (Chiewchanwit and Au 1995) . It is not yet known how alkyl chain length relates to glycol ether immunotoxicity. More studies are needed to adequately assess immunomodulatory trends among the glycol ethers.
We have demonstrated that topical exposure to 4.0 mg BE, whether given at the time of sensitization or at the time of challenge, signi cantly reduces the OXA-induced CHR in female BALB/c mice. It is notable that this effect does not exhibit a dose-response relationship, typically observed with chemical exposures, and is observed at only one dose/concentration of BE. A related phenomenon has been observed by other investigators in percutaneous BE exposure and kinetics studies, which have indicated that there may be an optimal dose or concentration of BE at which local absorption may occur due to kinetic factors associated speci cally with the cutaneous route. Johanson and Fernstrom (1988) reported that a solution of 40% BE in water produced peak blood concentrations of BE and BAA in the guinea pig, in accordance with measured permeability coef cients, with decreasing absorption at both higher and lower dilutions. A discussion of these data within the context of a physiologically based pharmacokinetic (PBPK) model of BE and BAA disposition in rats and humans suggested that higher concentrations of BE may have a xative effect on the skin leading to poor absorption, whereas lower concentrations may not have achieved a steady state for optimal absorption (Corley, Bormett, and Ghanayem 1994) . This explanation may have some relevance in the relationship between absorption of topically applied BE and modulation of the CHR; however, this was not directly investigated in the present study.
Unlike BE-induced hematotoxicity, the inhibitory effect of BE on the CHR following topical exposure did not appear to depend on the oxidative metabolism of BE to BAA by alcohol and aldehyde dehydrogenases. Topical exposure to BAA did not signi cantly alter this response. Instead, inhibition of BE metabolism via administration of the alcohol dehydrogenase inhibitor, MP, resulted in signi cantly greater reduction of the CHR than that produced by BE alone. Due to the known efciency of absorption demonstrated by glycol ethers in dermal absorption studies in both humans and laboratory animals (Kezic et al. 1997; Johanson and Fernstrom 1988) , it was expected that topical exposure to BE would result in its absorption into general circulation. It is unlikely, however, that systemic absorption of BE was related to the suppression of the CHR that we observed, because 10 days of oral exposure of up to 400 mg BE/kg/day had no effect on the CHR, even when sensitization was initiated on the 5th day of BE exposure and antigen challenge was carried out on the last day of exposure (data not shown). It is possible that the rapid clearance of BE from systemic circulation prevented its bioaccumulation and effective distribution to the local site of the CHR following oral BE exposures.
Mechanistic studies of the suppression of the CHR by exogenous chemical agents have indicated that the afferent arm of the response may be targeted. Particularly, in the cases of pentami-dine isethionate (Blaylock et al. 1991) and T-2 toxin (Blaylock et al. 1993) , topical exposures were found to disrupt MHC class II protein expression in LC, effectively reducing antigen presentation by these cells. In the present study, BE was effective in suppressing the CHR during the antigen challenge phase only when applied immediately following OXA challenge. It is possible that BE's interference with cutaneous immunity may involve disruption of antigen uptake, antigen transport or the chemoattraction and migration of immune cells. When BE was applied to the ear 1 to 10 hours, before or after OXA challenge, the reduction of ear swelling was not observed, indicating that the BE-induced immunomodulatory effect was time dependent and transient with respect to OXA. In clear contrast to both pentamidine isethionate and T-2 toxin, BE is not a known inhibitor of protein synthesis nor does it exhibit genotoxic activity. This is a likely explanation for why BE did not inhibit protein synthesis or signi cantly alter MHC class II protein expression in LC in vitro. We do not know the effect of topically applied BE on in vivo expression of MHC class II on LC. Other investigators have shown that exogenous glucocorticoids decrease the number of LC and the intensity of immunohistochemical staining of MHC class II in BALB/c mouse ear skin (Bernateck, Jonas, and Diezel 1996) . It is possible, in theory, that a stress response in association with BE cytotoxicity could result in the release of endogenous glucocorticoids. Such an effect would have potentially signi cant consequences on host resistance; however, these considerations were not within the scope of the present study. The intrinsic activity of BE as an organic solvent does suggest that it may disrupt cell membranes by altering physicochemical properties of the phospholipid structure. The cytotoxicity of BE may also have a signi cant role in its immunomodulatory activity via indirect mechanisms. Our results showed that BE did not signi cantly reduce LC viability, which indicated that LC are not particularly susceptible to the cytotoxic effects of BE. It is possible that a different skin cell population that is critical in the cutaneous immune response is susceptible to these effects. It is also possible that absorption of BE into localized blood vessels could have cytotoxic effects on endothelial cells within the vasculature, resulting in direct or indirect effects on local immune processes. These possibilities were not investigated in the present study.
In conclusion, our results indicate that suppression of the CHR by topically applied BE lacks dose-response characteristics. This xenobiotic-induced suppression does not require activation of BE and is, in fact, more potent in the absence of initiated oxidative metabolism by alcohol dehydrogenase . We speculate that BE may alter sensitization to OXA or subsequent elicitation of the CHR by essentially altering the milieu of allergen delivery and initial upregulation of the cutaneous immune response at the site of sensitization and challenge. Poor allergen transport in the local environment may reduce normal signaling associated with allergen exposures and disrupt allergen interaction with antigen presenting cells and T cells, leading to decreased induction and elicitation of the CHR.
